Choline fenofibrate 135 mg is a medication used to treat high cholesterol and triglyceride levels. It belongs to a class of drugs called fibrates [1].
How does choline fenofibrate work?
Choline fenofibrate functions by reducing the amount of triglycerides and increasing high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol, in the blood. This helps to lower the risk of cardiovascular events such as heart attacks and strokes [1].
When might a doctor prescribe choline fenofibrate 135 mg?
This dosage may be prescribed for patients who have hypertriglyceridemia, which is a condition characterized by very high levels of triglycerides in the blood. It is also used in combination with diet to treat patients with mixed dyslipidemia [1].
What are the potential side effects of choline fenofibrate?
Common side effects can include diarrhea, nausea, abdominal pain, headache, and increased liver enzymes. More serious side effects, though less common, can involve liver problems, pancreatitis, and muscle pain or weakness [1].
What is the difference between choline fenofibrate and fenofibric acid?
Choline fenofibrate is a prodrug that, once ingested, is hydrolyzed to fenofibric acid. Fenofibric acid is the active metabolite that exerts the therapeutic effects of the medication by acting on peroxisome proliferator-activated receptors (PPARα) [1].
When does the patent for choline fenofibrate expire?
Information regarding the patent expiration for choline fenofibrate can be found on DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent information for many pharmaceutical products, which is crucial for understanding market exclusivity and the potential for generic competition.
Are there alternative treatments for high cholesterol and triglycerides?
Yes, other treatment options include statins, bile acid sequestrants, cholesterol absorption inhibitors, and PCSK9 inhibitors, depending on the specific lipid profile and patient health status [1]. Lifestyle modifications, such as diet and exercise, are also fundamental components of managing dyslipidemia.